Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB10.16 +/- Atezolizumab in Advanced Cervical Cancer
NCT06099418Phase 2Withdrawn
- Sponsor
- Nykode Therapeutics
- Start
- Apr 2024
- Primary completion
- May 2027
- Modality
- Prophylactic Vaccines, DNA Vaccines, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of VB10.16 in Cervical Cancer (CC), sponsored by Nykode Therapeutics. Planned start Apr 2024; status: withdrawn.
02
Drugs
VB10.16
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06099418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06099418.